Migraine

Advances in the pathophysiology and treatment

Toshihiko Shimizu, Mamoru Shibata, Norihiro Suzuki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cortical spreading depression (CSD) is believed to be a phenomenon underlying migraine auras. The mutations of hemiplegic migraine genes are demonstrated to cause a reduction of CSD threshold. Consistently, tonabersat, which was developed for its ability to inhibit CSD, showed a preventive effect on attacks of migraine with aura. Besides, CSD has also been reported to activate the trigemino-vascular system, which subsequently causes migraine headache. The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) receptor is known as one of the nociceptive receptors, and exists in the dura mater and the trigeminal ganglion. We demonstrated that the dural TRPV1 receptor conducts pain sensation to the trigeminal nucleus caudalis via the trigeminal ganglion, which implies possible contribution of the TRPV1 receptor to migraine headache. Also our recent data have raised the possibility that the TRPV1 receptor may play a pivotal role for the chronification of migraine. Furthermore, the TRPV1 receptor regulates the release of calcitonin gene-related peptide (CGRP). CGRP has been recognized to be associated with migraine because of its potent effect for dilation of intracranial and extracranial blood vessels. Some newly developed CGRP receptor antagonists have revealed the efficaciousness for acute migraine attacks. The present review discusses the relevance of recent advance of basic migraine research to future migraine treatment.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalClinical Neurology
Volume51
Issue number2
Publication statusPublished - 2011 Feb

Fingerprint

Migraine Disorders
Cortical Spreading Depression
Trigeminal Ganglion
Therapeutics
Calcitonin Gene-Related Peptide
Blood Vessels
Calcitonin Gene-Related Peptide Receptors
Trigeminal Nuclei
Transient Receptor Potential Channels
Migraine with Aura
Dura Mater
Aptitude
Dilatation
Epilepsy
TRPV1 receptor
Pain
Mutation
Research
Genes

Keywords

  • CGRP receptor antagonists
  • Cortical spreading depression
  • Migraine
  • Trigemino-vascular system
  • TRPV1

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Migraine : Advances in the pathophysiology and treatment. / Shimizu, Toshihiko; Shibata, Mamoru; Suzuki, Norihiro.

In: Clinical Neurology, Vol. 51, No. 2, 02.2011, p. 103-109.

Research output: Contribution to journalArticle

Shimizu, T, Shibata, M & Suzuki, N 2011, 'Migraine: Advances in the pathophysiology and treatment', Clinical Neurology, vol. 51, no. 2, pp. 103-109.
Shimizu, Toshihiko ; Shibata, Mamoru ; Suzuki, Norihiro. / Migraine : Advances in the pathophysiology and treatment. In: Clinical Neurology. 2011 ; Vol. 51, No. 2. pp. 103-109.
@article{e4133bf1aed7434b93923c5349060e98,
title = "Migraine: Advances in the pathophysiology and treatment",
abstract = "Cortical spreading depression (CSD) is believed to be a phenomenon underlying migraine auras. The mutations of hemiplegic migraine genes are demonstrated to cause a reduction of CSD threshold. Consistently, tonabersat, which was developed for its ability to inhibit CSD, showed a preventive effect on attacks of migraine with aura. Besides, CSD has also been reported to activate the trigemino-vascular system, which subsequently causes migraine headache. The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) receptor is known as one of the nociceptive receptors, and exists in the dura mater and the trigeminal ganglion. We demonstrated that the dural TRPV1 receptor conducts pain sensation to the trigeminal nucleus caudalis via the trigeminal ganglion, which implies possible contribution of the TRPV1 receptor to migraine headache. Also our recent data have raised the possibility that the TRPV1 receptor may play a pivotal role for the chronification of migraine. Furthermore, the TRPV1 receptor regulates the release of calcitonin gene-related peptide (CGRP). CGRP has been recognized to be associated with migraine because of its potent effect for dilation of intracranial and extracranial blood vessels. Some newly developed CGRP receptor antagonists have revealed the efficaciousness for acute migraine attacks. The present review discusses the relevance of recent advance of basic migraine research to future migraine treatment.",
keywords = "CGRP receptor antagonists, Cortical spreading depression, Migraine, Trigemino-vascular system, TRPV1",
author = "Toshihiko Shimizu and Mamoru Shibata and Norihiro Suzuki",
year = "2011",
month = "2",
language = "English",
volume = "51",
pages = "103--109",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "2",

}

TY - JOUR

T1 - Migraine

T2 - Advances in the pathophysiology and treatment

AU - Shimizu, Toshihiko

AU - Shibata, Mamoru

AU - Suzuki, Norihiro

PY - 2011/2

Y1 - 2011/2

N2 - Cortical spreading depression (CSD) is believed to be a phenomenon underlying migraine auras. The mutations of hemiplegic migraine genes are demonstrated to cause a reduction of CSD threshold. Consistently, tonabersat, which was developed for its ability to inhibit CSD, showed a preventive effect on attacks of migraine with aura. Besides, CSD has also been reported to activate the trigemino-vascular system, which subsequently causes migraine headache. The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) receptor is known as one of the nociceptive receptors, and exists in the dura mater and the trigeminal ganglion. We demonstrated that the dural TRPV1 receptor conducts pain sensation to the trigeminal nucleus caudalis via the trigeminal ganglion, which implies possible contribution of the TRPV1 receptor to migraine headache. Also our recent data have raised the possibility that the TRPV1 receptor may play a pivotal role for the chronification of migraine. Furthermore, the TRPV1 receptor regulates the release of calcitonin gene-related peptide (CGRP). CGRP has been recognized to be associated with migraine because of its potent effect for dilation of intracranial and extracranial blood vessels. Some newly developed CGRP receptor antagonists have revealed the efficaciousness for acute migraine attacks. The present review discusses the relevance of recent advance of basic migraine research to future migraine treatment.

AB - Cortical spreading depression (CSD) is believed to be a phenomenon underlying migraine auras. The mutations of hemiplegic migraine genes are demonstrated to cause a reduction of CSD threshold. Consistently, tonabersat, which was developed for its ability to inhibit CSD, showed a preventive effect on attacks of migraine with aura. Besides, CSD has also been reported to activate the trigemino-vascular system, which subsequently causes migraine headache. The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) receptor is known as one of the nociceptive receptors, and exists in the dura mater and the trigeminal ganglion. We demonstrated that the dural TRPV1 receptor conducts pain sensation to the trigeminal nucleus caudalis via the trigeminal ganglion, which implies possible contribution of the TRPV1 receptor to migraine headache. Also our recent data have raised the possibility that the TRPV1 receptor may play a pivotal role for the chronification of migraine. Furthermore, the TRPV1 receptor regulates the release of calcitonin gene-related peptide (CGRP). CGRP has been recognized to be associated with migraine because of its potent effect for dilation of intracranial and extracranial blood vessels. Some newly developed CGRP receptor antagonists have revealed the efficaciousness for acute migraine attacks. The present review discusses the relevance of recent advance of basic migraine research to future migraine treatment.

KW - CGRP receptor antagonists

KW - Cortical spreading depression

KW - Migraine

KW - Trigemino-vascular system

KW - TRPV1

UR - http://www.scopus.com/inward/record.url?scp=79952554793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952554793&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 103

EP - 109

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 2

ER -